疏肝降脂颗粒治疗非酒精性脂肪肝的临床研究

发布时间：2018-05-08 03:40

本文选题：疏肝降脂颗粒 + 非酒精性脂肪肝　；参考：《广西中医药大学》2016年硕士论文

【摘要】：目的本研究旨在观察疏肝降脂颗粒治疗非酒精性脂肪肝的临床疗效及安全性。方法按纳入标准将60例患者随机分成治疗组30例、对照组30例,对照组在控制饮食、加强运动的基础上予水飞蓟宾胶囊口服,一次三粒,一天三次;治疗组在控制饮食、加强运动的基础上予疏肝降脂颗粒,每日一剂,分两次服用。两组疗程均为24周。观察比较两组患者治疗前、第24周的中医证侯积分、肝功能指标、血脂指标、肝脏彩超结果、安全性指标的变化情况并且进行统计分析和疗效评价。结果1、治疗组总有效率为86.21%,对照组为75.00%,治疗组优于对照组(P0.05)。治疗组各项症状体征较治疗前明显改善(P0.01)。对照组胁痛、乏力、食纳、口干口苦、烦躁易怒、恶心欲吐等证候较治疗前改善(P0.05),但对腹胀、大便稀溏改善不明显(PO.05)。治疗后组间比较,治疗组在胁痛、乏力、腹胀、食纳、口干口苦、恶心欲吐、烦躁易怒、大便稀溏的改善上优于对照组(PO.05)。2、治疗后两组ALT、AST、γ-GT值下降明显且较治疗前差异显著(P0.01)。治疗后两组间比较,ALT、AST、γ-GT复常率治疗组优于对照组(P0.05)。3、治疗后两组患者的TC、TG值下降明显且较治疗前差异显著(P0.01)。治疗后,两组间进行比较,治疗组的血脂指标均较对照组下降明显,具有统计学差异(P0.05)。4、治疗后两组患者肝脏彩超结果较治疗前改善明显(P0.05),具有统计学差异。治疗后两组间总有效率相比,差异具有统计学意义(P0.05),治疗组明显优于对照组。5、治疗前后两组患者无不良反应发生,安全性均良好。结论1、疏肝降脂颗粒能够显著改善非酒精性脂肪肝患者的症状和体征;2、疏肝降脂颗粒能够降低患者血脂,改善肝功能和肝脏彩超结果。
[Abstract]:Objective to observe the efficacy and safety of Shugan Jiangzhi granule in the treatment of non-alcoholic fatty liver. Methods according to the inclusion criteria, 60 patients were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with silybin capsule on the basis of diet control and exercise enhancement. Strengthen exercise on the basis of Shugan Jiangzhi granule, one dose daily, two times. The course of treatment was 24 weeks in both groups. To observe and compare the changes of TCM syndromes score, liver function index, blood lipid index, liver color ultrasound results, safety index and statistical analysis and evaluation of curative effect between the two groups before and after treatment. Results 1. The total effective rate of the treatment group was 86.21 and that of the control group was 75.00. The treatment group was superior to the control group (P 0.05). The symptoms and signs of the treatment group were significantly improved compared with those before treatment (P 0.01). In the control group, the symptoms of hypochondriac pain, fatigue, food intake, dry mouth, irritability and irritability, nausea and vomiting were improved compared with those before treatment, but the symptoms of abdominal distension and loose stools were not significantly improved. After treatment, the improvement of hypochondriac pain, fatigue, abdominal distension, food intake, dry mouth, nausea and vomiting, irritability and irritability, loose stool in the treatment group was better than that in the control group. After treatment, the values of alt AST, 纬 -GT in the two groups decreased significantly and the difference was significant compared with that before treatment (P0.01). After treatment, the recovery rate of alt AST and 纬 -GT in the treatment group was better than that in the control group (P 0.05 路3). After treatment, the TG value of the two groups decreased significantly and the difference was significant compared with that before treatment (P 0.01). After treatment, compared with the control group, the blood lipid index in the treatment group was significantly lower than that in the control group, with statistical difference (P0.05. 4). After treatment, the liver color ultrasound results of the two groups were significantly improved than that before treatment (P0.05), and the difference was statistically significant. After treatment, the total effective rate of the two groups was significantly higher than that of the control group, the difference was statistically significant (P 0.05), and the treatment group was superior to the control group (.5). There was no adverse reaction and the safety of the two groups was good before and after treatment. Conclusion 1. Shugan Jiangzhi granule can significantly improve the symptoms and signs of non-alcoholic fatty liver patients, Shugan Jiangzhi granule can reduce blood lipid, improve liver function and liver color ultrasound results. 2.
【学位授予单位】：广西中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】